people in the general population (4). HCM is a clinically and genetically heterogenous disease, associated with >1,500 mutations in $11 major genes (and a variety of other susceptibility genes with lesser evidence for pathogenicity), encoding proteins of the cardiac sarcomere, adjacent Z disk, and calcium handling (5) .
Although HCM is associated with substantial diversity in morphological expression (6) , clinical diagnosis usually occurs with recognition of the characteristic disease phenotype, that is, left ventricular (LV) hypertrophy without chamber dilatation in the absence of another cardiac or systemic disease capable of producing the magnitude of hypertrophy evident (1, 6) . Neither systolic anterior motion of the mitral valve, hyperdynamic LV function, or identification of pathogenic sarcomere mutations is obligatory for the clinical diagnosis of HCM (2) .
Atrial fibrillation is a common cause of morbidity in HCM, occurring in z20% of patients, although usually after 30 years of age (1, 2) . Notably, the clinical presentation and course are diverse, with unexpected sudden death in the young the most visible disease complication.
SUDDEN DEATH RISK
A major impetus in HCM has been the identification of those patients at increased risk for sudden death. Indeed, a risk-stratification algorithm has been largely effective in identifying those people at highest risk who are eligible for primary prevention of sudden death with an implantable cardioverter-defibrillator (ICD) (7-10), thereby markedly reducing HCM-related mortality to 0.5% per year (7).
Sudden death events are attributable to potentially lethal ventricular tachyarrhythmias (ventricular tachycardia/ ventricular fibrillation) and usually occur in the presence of $1 the major risk markers (appropriate ICD interventions of 4% per year in patients implanted for primary prevention) (7-10). Some HCM patients may nevertheless die suddenly in the absence of all conventional risk factors (0.6% per year in non-ICD populations) (7).
Indeed, in the presence of underlying (and often unsuspected) HCM, participation in high-intensity competitive sports may itself promote ventricular tachycardia/ventricular fibrillation and act as a potent (yet modifiable) independent risk factor, even in the absence of conventional risk markers intrinsic to the disease process (3, 7, 11, 12) . Notably, the underlying electrophysiological substrate in HCM is unpredictable (1,2,7-10) and potentially subject to instability by interaction with physiological stresses inherent in athletic training and competition, including alternations in hydration, blood volume, and electrolytes, as well as the catecholamine surge.
Given these principles, it is difficult to apply conventional risk-stratification strategies to make reliable eligibility decisions specifically for aspiring competitive athletes with HCM. The estimation of risk level based on phenotypic expression (e.g., specific LV wall thickness or LV outflow tract gradient) or other aspects of the clinical profile is a highly problematic endeavor. Such considerations are influenced by the morphological diversity of HCM and the unpredictable instability of the myocardial substrate, as well as the additive risk created by intense training and competition in susceptible patients with HCM (3). Therefore, in HCM, the most common cause of sudden death in young athletes (1-3), engagement in intense competitive sports is itself an acknowledged modifiable risk factor (1-3).
These observations necessitate conservative and prudent recommendations regarding sports eligibility applied in a homogeneous fashion across the broad HCM disease spectrum. This may unavoidably result in recommendations for disqualification in some athletes with HCM probably at low risk and unlikely to ever experience sudden death, who could potentially compete and train safely. Notably, the present disqualification/eligibility guidelines for competitive athletes with HCM do not differ measurably from those previously stated in the 36th
Bethesda Conference (11), because alternative new data or insights have not emerged sufficient to substantially alter the recommendations.
On the other hand, the present American Heart Association/American College of Cardiology recommendations do not strictly exclude in absolute terms fully informed athletes from participating in competitive athletic programs as long as such a decision is ultimately made in concert with their physician and third-party interests (e.g., high schools and colleges). Although this expert consensus report serves as a prudent guideline regarding sports eligibility or disqualification, there will always be tolerance in the system for some degree of flexibility, individual responsibility, and choice in making these decisions for individual student athlete-patients.
Genotype Positive-Phenotype Negative
An increasing number of HCM family members are recognized with documented pathogenic (disease-causing) sarcomere mutations, but in the absence of a clinical HCM phenotype (i.e., LV hypertrophy) (5, 13) . Such patients have been identified at a broad range of ages, although they are most commonly adolescents and young adults, and some wish to engage in competitive sports.
Spontaneous conversion to LV hypertrophy in this subset appears to occur most often in adolescence between 12 and 20 years of age (1,13) but has also been observed in midlife and beyond (14, 15) . Nevertheless, such changes are unpredictable, and some genetically affected people will probably never develop the HCM phenotype.
Spontaneous morphological conversions are not usually accompanied by cardiac symptoms, disease progression, or events (1,2,13-15). However, once LV hypertrophy (5, (16) (17) (18) (19) . At present, the risk for sudden death in gene-positive-phenotype-negative family members appears to be extremely low and likely no different from the risk in the general population of the same age without heart disease (5, 20) . CMR imaging is also an important consideration in family members who are gene positive and judged to be phenotype negative based on echocardiography, because areas of segmental LV hypertrophy may be detected only by CMR, particularly in the anterolateral free wall and apex (6, 21) . 
MYOCARDITIS

General Considerations
Myocarditis commonly presents with disproportionate dyspnea on exertion, chest pain, and arrhythmias. It can also present as an acute myocardial infarction-like syndrome with sudden death in the presence of normal epicardial coronary arteries (39) (40) (41) (42) (43) (44) . The contribution of myocarditis to cardiovascular sudden death varies significantly with age, causing cardiovascular sudden death in z2% of infants, 5% of children, and 4% to 7.5% of athletes (3, 40) . Higher rates of myocarditis are occasionally reported in postmortem studies from general populations younger than 35 to 40 years of age (41) . Most cardiovascular sudden deaths attributable to myocarditis occur in males (42) , and in some cases, myocarditis results in sudden death without antecedent symptoms or macroscopic cardiac abnormalities (40, 42, 43) .
The data linking myocarditis to sudden death are strong and include autopsy studies and experimental myocarditis 
At present, it is unresolved whether resolution of myocarditis-related LGE should be required to permit return to competitive sports. 
